Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preladenant extension study in moderate to severe Parkinson's disease
2009-015162-57Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of preladenant in Parkinson's disease (PD) (2 arms), sponsored by Merck & Co. Primary endpoints: Long-term safety and tolerability of preladenant, Change from baseline in Montreal Cognitive Assessment score and 4 more. Started Jan 2011; status: completed.
02
Drugs
preladenant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2009-015162-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015162-57.